Elevance Health, Inc. ELV SPX
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -1.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELV Elevance Health, Inc. SPX | 393.19 | 16.67 | $85.39B | 1.75% | - | 12.09% | 8.34% | -1.33% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.90B | 20.19B | 20.29B | 21.46B | 21.40B | 21.71B | 22.52B | 22.41B | 22.43B | 22.68B | 22.54B | 22.94B | 23.25B | 23.37B | 24.67B | 25.47B | 26.67B | 27.41B | 29.62B | 29.26B | 31.16B | 31.82B | 32.38B | 33.85B | 35.82B | 38.09B | 38.63B | 39.94B | 42.17B | 43.67B | 42.85B | 42.58B | 43.89B | - | - | 48.89B | 49.78B | 50.71B | 49.75B | 50.18B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 1.22B | - | 1.57B | 1.50B | 1.08B | - | 1.59B | 1.23B | 982.00M | - | 1.87B | 1.56B | 1.25B | - | 1.94B | 1.43B | 1.53B | - | 2.19B | 3.36B | 201.00M | - | 2.16B | 2.08B | 2.06B | 2.43B | 2.35B | 2.25B | 2.83B | 2.63B | 1.76B | 3.02B | 2.77B | - | - | 3.14B | 2.63B | 1.76B | 581.00M | 2.66B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 344.00M | 341.00M | 351.00M | 366.00M | 357.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.80B | 2.29B | 1.41B | 215.00M | 2.30B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 613.00M | 548.00M | 219.00M | -331.00M | 544.00M |
| Net Income | 654.80M | 180.90M | 703.00M | 780.60M | 617.80M | 368.40M | 1.01B | 855.00M | 747.00M | 1.23B | 1.31B | 1.05B | 960.00M | 424.00M | 1.55B | 1.14B | 1.18B | 934.00M | 1.52B | 2.28B | 222.00M | 551.00M | 1.67B | 1.79B | 1.51B | 1.79B | 1.64B | 1.60B | 1.99B | 1.85B | 1.29B | 2.25B | 2.30B | - | - | 2.18B | 1.74B | 1.19B | 547.00M | 1.76B |
| Diluted EPS | 2.43 | 0.68 | 2.63 | 2.91 | 2.30 | 1.37 | 3.73 | 3.16 | 2.80 | 4.67 | 4.99 | 3.98 | 3.62 | 1.61 | 5.91 | 4.36 | 4.55 | 3.62 | 5.94 | 8.91 | 0.87 | 2.19 | 6.71 | 7.25 | 6.13 | 7.32 | 6.73 | 6.62 | 8.30 | 7.79 | 5.45 | 9.59 | 9.85 | - | - | 9.61 | 7.72 | 5.32 | 2.47 | 8.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.17B | 61.25B | 64.94B | 58.70B | 60.71B | 61.50B | 71.02B | 73.87B | 79.16B | 84.86B | 90.04B | 92.11B | 104.21B | 121.87B | - | 156.59B | 171.34B | 176.81B | 199.12B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | 4.35B | 4.18B | 4.08B | 3.78B | 3.62B | 4.00B | 4.42B | 4.75B | 4.80B | 4.17B | 5.43B | 6.00B | 6.36B | - | 8.45B | 8.74B | 9.09B | 8.11B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 851.00M | 1.03B | 1.19B | 1.40B |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.60B | 7.71B | 7.90B | 6.71B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 3.35B | 2.49B | 4.75B | 2.89B | 2.65B | 2.66B | 2.49B | 2.57B | 2.56B | 2.47B | 3.84B | 3.75B | 4.81B | 4.57B | - | 5.89B | 5.99B | 5.98B | 5.66B |
| Diluted EPS | 5.56 | 4.76 | 9.88 | 6.94 | 7.25 | 8.18 | 8.20 | 8.99 | 9.38 | 9.21 | 14.35 | 14.19 | 18.47 | 17.98 | - | 24.81 | 25.22 | 25.68 | 25.21 |
Compounded Sales Growth
| 5 Years: | 8.34% |
| 1 Year: | 2.60% |
Compounded Profit Growth
| 5 Years: | -1.33% |
| 1 Year: | -16.80% |
Stock Price Performance
| 1 Year: | +4.62% |
| 6 Months: | +18.25% |
| 3 Months: | +23.63% |
| 1 Month: | +4.40% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 48.40B | 52.13B | 50.17B | 52.16B | 58.96B | 59.57B | 61.68B | 61.72B | 65.08B | 70.54B | 71.57B | 77.45B | 86.61B | 97.46B | 102.75B | 108.93B | 116.89B | 121.49B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cash & Equivalents | 2.60B | 2.77B | 2.18B | 4.82B | 1.79B | 2.20B | 2.48B | 1.58B | 2.15B | 2.11B | 4.08B | 3.61B | 3.93B | 4.94B | 5.74B | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.08B | 7.90B | 8.01B | 10.07B |
| Total Liabilities | - | - | 26.97B | 27.26B | 26.35B | 28.88B | 35.15B | 34.81B | 37.42B | 38.67B | 39.98B | 44.04B | 43.03B | 45.73B | 53.42B | 61.33B | 66.42B | 69.52B | 75.46B | 77.47B |
| Current Liabilities | - | - | 15.02B | 14.67B | 14.01B | 15.90B | 15.99B | 16.35B | 18.75B | 19.09B | 21.29B | 23.36B | 21.96B | 23.53B | 29.45B | 34.88B | - | - | - | - |
| Long Term Debt | - | - | 7.83B | 8.34B | 8.15B | 8.47B | 14.17B | 13.57B | 14.02B | 15.32B | 14.36B | 17.38B | 17.22B | 17.79B | 19.34B | 21.16B | 22.35B | 23.25B | 29.22B | 30.80B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.11B | 25.12B | 31.23B | 32.05B |
| Total Equity | 24.58B | 22.99B | 21.43B | 24.86B | 23.81B | 23.29B | 23.80B | 24.77B | 24.25B | 23.05B | 25.10B | 26.50B | 28.54B | 31.73B | 33.20B | 36.06B | 36.24B | 39.31B | 41.31B | 43.88B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 237.96M | 233.07M | 227.48M | 220.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.34B | 2.54B | 3.04B | 1.42B | 3.37B | 2.74B | 3.05B | 3.37B | 4.21B | 3.27B | 4.18B | 3.83B | 6.06B | 10.69B | - | 8.40B | 8.06B | 5.81B | 4.29B |
| Investing Cash Flow | -768.90M | 616.20M | 3.00B | -1.27B | -942.00M | -4.55B | -2.23B | -974.90M | -1.15B | -514.00M | -5.08B | -1.26B | -2.79B | -7.32B | - | -4.56B | -5.57B | -5.17B | -1.34B |
| Financing Cash Flow | -3.41B | -3.74B | -3.40B | -3.17B | -2.02B | 2.09B | -1.72B | -1.82B | -3.09B | -799.00M | 427.00M | -2.24B | -2.27B | -2.57B | - | -1.32B | -3.35B | 1.19B | -1.74B |
| Capital Expenditure | -322.00M | -345.60M | -378.40M | -451.40M | -519.50M | -544.90M | -646.50M | -714.60M | -638.20M | -584.00M | -791.00M | -1.21B | -1.08B | -1.02B | - | -1.15B | -1.30B | -1.26B | -1.12B |
| Free Cash Flow | 4.02B | 2.19B | 2.66B | 965.30M | 2.85B | 2.20B | 2.41B | 2.65B | 3.57B | 2.69B | 3.39B | 2.62B | 4.98B | 9.67B | - | 7.25B | 6.76B | 4.55B | 3.17B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.52B | -860.00M | 1.83B | 1.21B |
| Share Buybacks | 6.15B | 3.28B | 2.64B | 4.36B | 3.04B | 2.50B | 1.62B | 3.00B | 1.52B | 0 | 2.00B | 1.69B | 1.70B | 2.70B | 1.90B | 2.32B | 2.68B | 2.90B | 2.60B |
| Dividends Paid | - | - | - | 0 | 357.80M | 367.10M | 448.00M | 480.70M | 656.60M | 684.00M | 705.00M | 776.00M | 818.00M | 954.00M | 1.10B | 1.23B | 1.40B | 1.51B | 1.53B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | 7.1% | 6.4% | 6.9% | 6.2% | 5.9% | 5.6% | 6.0% | 6.0% | 5.7% | 4.6% | 5.9% | 5.8% | 5.2% | - | 5.4% | 5.1% | 5.1% | 4.1% |
| Net Margin % | 5.5% | 4.1% | 7.3% | 4.9% | 4.4% | 4.3% | 3.5% | 3.5% | 3.2% | 2.9% | 4.3% | 4.1% | 4.6% | 3.8% | - | 3.8% | 3.5% | 3.4% | 2.8% |
| ROE % | 14.6% | 11.6% | 19.1% | 12.1% | 11.4% | 11.2% | 10.1% | 10.6% | 11.1% | 9.8% | 14.5% | 13.1% | 15.2% | 13.8% | - | 16.3% | 15.2% | 14.5% | 12.9% |
| ROCE % | - | 13.0% | 11.2% | 11.3% | 10.4% | 8.4% | 9.3% | 10.3% | 11.2% | 11.0% | 8.8% | 10.9% | 11.1% | 11.1% | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.16% | 19.89M | $7.82B |
| 2 | Vanguard Capital Management LLC | 6.61% | 14.35M | $5.64B |
| 3 | State Street Corporation | 4.74% | 10.29M | $4.05B |
| 4 | Wellington Management Group, LLP | 3.79% | 8.23M | $3.24B |
| 5 | Vanguard Portfolio Management LLC | 2.93% | 6.36M | $2.50B |
| 6 | Sanders Capital, LLC | 2.71% | 5.89M | $2.32B |
| 7 | Geode Capital Management, LLC | 2.39% | 5.19M | $2.04B |
| 8 | Artisan Partners Limited Partnership | 2.36% | 5.13M | $2.02B |
| 9 | Invesco Ltd. | 2.22% | 4.82M | $1.89B |
| 10 | Harris Associates L.P. | 2.21% | 4.80M | $1.89B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELV